Akebia Therapeutics Inc.

AKBA | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.94

+$0.02 (+2.65%)

At close: Sep 21, 2026, 4:00 PM ET

$0.95

+$0.01 (+0.95%)

Pre-market: Sep 22, 2026, 4:36 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.65%

(1D)

Rating

Updated: Aug 25, 2026

38.5

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $251.76M

1D Range

0.92 0.95

52W Range

0.81 3.20

Valuation (TTM)

PE -8.55

PB 10.06

EV/EBITDA -8.34

Valuation (NTM)

Forward PE 15.33

Forward PEG -0.07

Price Target $1

Cash Flow

FCF Yield 16.0%

SBC Adj. FCF Yield 10.7%

SBC Impact -33.1%

Margins

Gross Margin 79.5%

Operating Margin -6.9%

FCF Margin 18.4%

Growth (CAGR)

Revenue 3Y | 5Y 3.0% | -0.3%

Dil EPS 3Y | 5Y 28.1% | 51.8%

FCF 3Y | 5Y 9010.9% | 109.8%

Returns

ROA -8.5%

ROE -93.7%

ROIC -7.1%

Financial Health

Net Cash

$105.99M

Current Ratio 1.43

Interest Coverage -1.90

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering...

Sector Healthcare

Industry Biotechnology

Employees 194

IPO Date Mar 19, 2014

Website www.akebia.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+6.38%

Buy (3)

Hold (1)

Sell (0)

Analyst Details ➞